The Effect of a TLR4 Agonist/Cationic Liposome Adjuvant on Varicella-Zoster Virus Glycoprotein E Vaccine Efficacy: Antigen Presentation, Uptake, and Delivery to Lymph Nodes

Adjuvant CIA09, composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-based cationic liposomes and the toll-like receptor 4 agonist de-O-acylated lipooligosaccharide (dLOS), has been shown to enhance antibody and cellular immune responses to varicella-zoster virus (VZV) glycoprotein E (gE), recombinant tuberculosis vaccine antigen, and inactivated Japanese encephalitis vaccine. In this study, we investigated its modes of action using VZV gE as a model antigen. Liposomes adsorbed gE and cooperatively with dLOS promoted endocytosis-mediated cellular uptake of gE by mouse dendritic cells in vitro. CIA09 increased the stability and cellular uptake of the antigen at the muscle site of injection, and induced immune cell recruitment and cytokine and chemokine production, which led to efficient antigen delivery to draining lymph nodes. Mouse bone marrow-derived dendritic cells, pulsed with CIA09-adjuvanted gE, efficiently presented gE to antigen-specific T cells, inducing Th1-type biased immunity, as shown by high IFN-γ production. The data indicate that liposomes and dLOS cooperate in the adjuvant activity of CIA09 by promoting antigen uptake and delivery to lymph nodes as well as antigen presentation to T cells.

[1]  C. Rosano,et al.  Modulation of immune responses using adjuvants to facilitate therapeutic vaccination , 2020, Immunological reviews.

[2]  S. Muller,et al.  Novel trisaccharide based phospholipids as immunomodulators. , 2019, International immunopharmacology.

[3]  Zhihui Liang,et al.  Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. , 2019, Vaccine.

[4]  A. Ko,et al.  Efficient induction of cell-mediated immunity to varicella-zoster virus glycoprotein E co-lyophilized with a cationic liposome-based adjuvant in mice. , 2019, Vaccine.

[5]  Ting Wang,et al.  Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization , 2017, Journal of Controlled Release.

[6]  S. Amel Jamehdar,et al.  Increasing Cellular Immune Response in Liposomal Formulations of DOTAP Encapsulated by Fusion Protein Hspx, PPE44, And Esxv, as a Potential Tuberculosis Vaccine Candidate. , 2019, Reports of biochemistry & molecular biology.

[7]  H. Kiyono,et al.  Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC‐chol confers antigen‐mediated protective immunity against Streptococcus pneumoniae infections in mice , 2018, International immunopharmacology.

[8]  R. Nisini,et al.  The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases , 2018, Front. Immunol..

[9]  A. Ko,et al.  Comparison of the adjuvanticity of two adjuvant formulations containing de-O-acylated lipooligosaccharide on Japanese encephalitis vaccine in mice , 2018, Archives of pharmacal research.

[10]  A. Ko,et al.  Potentiation of Th1-Type Immune Responses to Mycobacterium tuberculosis Antigens in Mice by Cationic Liposomes Combined with De-O-Acylated Lipooligosaccharide. , 2018, Journal of microbiology and biotechnology.

[11]  S. Muller,et al.  An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy. , 2017, Trends in pharmacological sciences.

[12]  A. Ko,et al.  Increased Immunogenicity and Protective Efficacy of a P. aeruginosa Vaccine in Mice Using an Alum and De-O-Acylated Lipooligosaccharide Adjuvant System. , 2017, Journal of microbiology and biotechnology.

[13]  A. Didierlaurent,et al.  Adjuvant system AS01: helping to overcome the challenges of modern vaccines , 2017, Expert review of vaccines.

[14]  A. Ko,et al.  A De-O-acylated Lipooligosaccharide-Based Adjuvant System Promotes Antibody and Th1-Type Immune Responses to H1N1 Pandemic Influenza Vaccine in Mice , 2016, BioMed research international.

[15]  T. Rades,et al.  Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators , 2016, Pharmaceutics.

[16]  Z. Beck,et al.  Liposomal adjuvants for human vaccines , 2016, Expert opinion on drug delivery.

[17]  P. Liu,et al.  Lymphatic-targeted cationic liposomes: A robust vaccine adjuvant for promoting long-term immunological memory. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[18]  N. Garçon,et al.  Vaccine Adjuvants: from 1920 to 2015 and Beyond , 2015, Vaccines.

[19]  T. Ottenhoff,et al.  A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. , 2014, Vaccine.

[20]  P. Massari,et al.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands , 2014, Vaccines.

[21]  Y. Cho,et al.  Characterization of the Structure and Immunostimulatory Activity of a Vaccine Adjuvant, De-O-Acylated Lipooligosaccharide , 2014, PloS one.

[22]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[23]  Douglas M. Smith,et al.  Applications of nanotechnology for immunology , 2013, Nature Reviews Immunology.

[24]  S. Koernig,et al.  Combination of adjuvants: the future of vaccine design , 2013, Expert review of vaccines.

[25]  Y. Perrie,et al.  A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant , 2013, Human vaccines & immunotherapeutics.

[26]  Hong-Jin Kim,et al.  Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice. , 2012, Vaccine.

[27]  J. Chun,et al.  A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice. , 2011, International immunopharmacology.

[28]  E. Oviedo-Orta,et al.  Progress in understanding adjuvant immunotoxicity mechanisms. , 2011, Toxicology letters.

[29]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[30]  P. Andersen,et al.  Cationic liposomes as vaccine adjuvants , 2007, Expert review of vaccines.

[31]  王策,et al.  The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses , 2011 .

[32]  S. Reed,et al.  Mode of action of adjuvants: implications for vaccine safety and design. , 2010, Biologicals : journal of the International Association of Biological Standardization.

[33]  Yvonne Perrie,et al.  Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[34]  Yvonne Perrie,et al.  Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[35]  E. De Gregorio,et al.  Immunology of TLR-independent vaccine adjuvants. , 2009, Current opinion in immunology.

[36]  Shizuo Akira,et al.  The roles of TLRs, RLRs and NLRs in pathogen recognition. , 2009, International immunology.

[37]  Y. Perrie,et al.  Liposome-based cationic adjuvant formulations (CAF): Past, present, and future , 2009, Journal of liposome research.

[38]  P. Andersen,et al.  Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements , 2008, PloS one.

[39]  C. Hackett,et al.  Rationally-designed vaccine adjuvants: separating efficacy from toxicity. , 2008, Frontiers in bioscience : a journal and virtual library.

[40]  Leaf Huang,et al.  Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. , 2007, Molecular immunology.

[41]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[42]  C. Geisler,et al.  The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes , 2007, Immunology.

[43]  Doo-sik Kim,et al.  A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. , 2006, Vaccine.

[44]  Leaf Huang,et al.  Immunostimulation of dendritic cells by cationic liposomes , 2006, Molecular membrane biology.

[45]  P. Andersen,et al.  Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. , 2005, Biochimica et biophysica acta.

[46]  E. B. Lindblad.  Aluminium compounds for use in vaccines , 2004, Immunology and cell biology.

[47]  N. Valiante,et al.  Recent advances in the discovery and delivery of vaccine adjuvants , 2003, Nature Reviews Drug Discovery.

[48]  Laurence Zitvogel,et al.  Antigen presentation and T cell stimulation by dendritic cells. , 2002, Annual review of immunology.

[49]  G. Gregoriadis,et al.  Liposome-mediated DNA vaccination: the effect of vesicle composition. , 2001, Vaccine.

[50]  C. H. Lee,et al.  Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation. , 1999, Analytical biochemistry.

[51]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.